Bradley McGregor, MD, discusses future research in metastatic castration-resistant prostate cancer.
Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses future research in metastatic castration-resistant prostate cancer (mCRPC).
The use of novel imaging with prostate-specific membrane antigen PET could help identify oligometastatic disease, which, with the use of aggressive local therapies, could delay the need for prolonged systemic therapy, says McGregor.
Additionally, the recent approvals of the PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) were pivotal additions to the prostate cancer paradigm, McGregor explains.
Immunotherapy has not been particularly effective in prostate cancer. However, findings from the interim analysis of cohort 6 of the phase Ib COSMIC-021 study showed synergistic activity with the combination of cabozantinib (Cabometyx)and atezolizumab (Tecentriq) in patients with mCRPC who have progressed on abiraterone acetate (Zytiga) and enzalutamide (Xtandi). As such, results from the pivotal phase 3 study are highly anticipated, McGregor concludes.